| 2020-MATO-68833 | |
| Researchers at Purdue University have developed an immunotherapy approach combining cell therapy and a small molecule inhibitor to treat glioblastoma. This devastating cancer is characterized by the heterogeneity of tumor antigens expressed on the surface of the tumor cells. This heterogeneity makes glioblastoma difficult to treat using mono-immunotherapeutic approaches, a treatment option that typically results in resistance to the therapy. Therefore there is a critical need to develop approaches to treat glioblastoma to overcome the heterogeneity of the disease. The technology developed consists of genetically-engineered natural killer (NK) cells and a small molecule inhibitor. The NK cells target two glioblastoma antigens while also blocking adenosine mediated immunosuppression to increase immune cell infiltration in the tumor microenvironment. Along with the cell therapy small molecule based autophagy inhibition promotes intra-tumoral NK cell infiltration, further increasing the effectiveness of the therapy. The genetic construct has been successfully expressed in NK cells as seen by flow cytometry analysis. NK cells engineered with the construct display significant increases in the killing of a patient-derived glioblastoma cell line when compared to wild-type NK cells. This technology provides the first combination immunotherapy approach toward glioblastoma treatment providing the potential to drastically increase patient survival. Advantages: -Multi-Faceted Glioblastoma Treatment Option -Increases Immune Cell Infiltration Potential applications: -Glioblastoma Therapy -Combination Therapy |
|
|
|
|
Oct 21, 2020
PCT-Patent
WO
(None)
(None)
Oct 21, 2019
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
